AMBRA1 Inhibits Non‐Small Cell Lung Cancer Progression Through miR ‐1178/p53/ CDK2 ‐Regulated Cell Cycle Arrest
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Jing Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, Henan Province, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cyclin-Dependent Kinase 2. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science and Technology Tackling Programme Project in Henan Province.
Abstract (Originalsprache)
AMBRA1 is associated with a variety of pathological processes in cancer cells, but may have different functions in different tumour microenvironments or genetic backgrounds. In this study, the function and regulatory mechanisms of AMBRA1 were explored in the progression of non‐small cell lung cancer (NSCLC). The abnormally expressed miRNAs in AMBRA1‐overexpressed and differentially expressed genes in miR‐1178‐knockdown NSCLC cells were validated by RNA sequencing. Cell viability, proliferation, invasion, apoptosis, and cell cycle were tested through Cell Counting Kit‐8 (CCK‐8), EdU, colony formation, transwell, and flow cytometry. A mouse tumour xenograft model was conducted to assess the roles of the AMBRA1‐miR‐1178 axis on NSCLC progression in vivo. AMBRA1 overexpression suppressed NSCLC cell proliferation and invasion, while promoting apoptosis and G0/G1 phase cell cycle arrest in vitro, and inhibited tumour growth in vivo. RNA sequencing revealed miR‐1178 as a target of AMBRA1. miR‐1178 overexpression partially weakened the suppressive function of AMBRA1 on cell malignant biological behaviours. p53 and CDK2 were confirmed as the downstream targets of miR‐1178. Silencing p53 or overexpressing CDK2 reversed the repressive effects of AMBRA1 on the development of NSCLC cells. AMBRA1 may suppress the malignant phenotype of NSCLC cells via regulating the miR‐1178‐p53‐CDK2 signalling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, Henan Province, China.
- Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
ORCID-Profile: Zhigang Zhao
Förderung
- Medical Science and Technology Tackling Programme Project in Henan Province
Zitieren
APA
Feng, J., Li, S., Li, L., Du, Z., Yang, G., Zhao, Z., Fan, X., Wang, N., & Zhao, Z. (2025). AMBRA1 Inhibits Non‐Small Cell Lung Cancer Progression Through miR ‐1178/p53/ CDK2 ‐Regulated Cell Cycle Arrest. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70610
Vancouver
Feng J, Li S, Li L, Du Z, Yang G, Zhao Z, et al. AMBRA1 Inhibits Non‐Small Cell Lung Cancer Progression Through miR ‐1178/p53/ CDK2 ‐Regulated Cell Cycle Arrest. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70610
BibTeX
@article{Feng2025,
author = {Feng, Jing and Li, Shan and Li, Laihua and Du, Zhiqiang and Yang, Guangying and Zhao, Zhi and Fan, Xueke and Wang, Na and Zhao, Zhigang},
title = {AMBRA1 Inhibits Non‐Small Cell Lung Cancer Progression Through miR ‐1178/p53/ CDK2 ‐Regulated Cell Cycle Arrest},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70610}
}
EUVIMED